1. Ducatman BS, Wang HH. Breast. In: Cibas ES, Ducatman BS, editors. Cytology. Diagnostic principles and clinical correlates. 3rd ed. Edinburgh: Saunders; 2009. p. 221-54.

2. DeMay RM. Practical Principles of Cytopathology. Chicago: ASCP Press; 1999. p. 257-278.

3. Fischer AH, Schwartz MR, Moriarty AT Wilbur DC, et al. Immunohistochemistry practices of cytopathology laboratories: A survey of participants in the College of American Pathologists nongynecologic cytopathology education program. Arch Pathol Lab Med. 2014;138:1167-1172.

4. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(7):e48-e72.

5. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256.

6. Cimino-Mathews A, Subhawong AP, Illei PB, et al. GATA3 expression in breast carcinoma: Utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol. 2013; 44(7):1341-1349.

7. Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA-3 expression in tumors and normal tissues: A useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 2012;138:57-64.

8. Lester SC. The Breast. In: Kumar V; Abbas AK; Aster JC, ed. Robbins and Cotran Pathologic Basis of Disease, Professional Edition, 9th edition. Philadelphia: Saunders; p. 1044-1073.

9. Breast Cancer in Men. The American Cancer Society. http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-what-is-breast-cancer-in-men

10. Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007 May;103(1):11-21.

11. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811.

12. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013;119(9):1611.

13. Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, Jahn M, Costa SD. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013 Jan;137(2):465-70.

14. Vetto J, Jun SY, Paduch D, Eppich H, Shih R, Padduch D. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg. 1999;177(5):379.

15. Joshi A, Kapila K, Verma K. Fine needle aspiration cytology in the management of male breast masses. Nineteen years of experience. Acta Cytol. 1999;43(3):334.

16. Westenend PJ, Jobse C. Evaluation of fine-needle aspiration cytology of breast masses in males. Cancer. 2002;96(2):101.